Table 2. Univariate and multivariate analyses of survival in 70 patients with pancreatic cancer according to clinicopathologic variables and GalNAc-T3 or -T6 expression.
|
Univariate
|
Multivariate
|
|||||
|---|---|---|---|---|---|---|
| Risk factors | Hazard | 95% CI | P | Hazard | 95% CI | P |
| GalNAc-T3 expression | 0.96 | 0.51–1.78 | 0.892 | |||
| GalNAc-T6 expression | 0.52 | 0.30–0.88 | 0.014 | 0.53 | 0.31–0.92 | 0.024 |
| Poor differentiation | 3.22 | 1.48–7.00 | 0.003 | |||
| Tumour in head of pancreas | 0.91 | 0.53–1.58 | 0.743 | |||
| Increasing tumour size | 1.86 | 0.87–3.95 | 0.109 | |||
| Presence of LN metastasis | 1.46 | 0.85–2.53 | 0.175 | |||
| Advanced stage (III/IV) | 3.97 | 2.10–7.50 | <0.001 | 3.65 | 1.86–7.16 | <0.001 |
| Positive tumour margin | 1.49 | 0.89–2.51 | 0.132 | |||
| Presence of LI | 1.62 | 0.90–2.88 | 0.103 | |||
| Presence of VI | 1.27 | 0.73–2.20 | 0.400 | |||
| Presence of PNI | 1.25 | 0.69–2.26 | 0.463 | |||
| Highly serum CA19-9 level | 1.60 | 0.86–2.99 | 0.137 | |||
| Highly serum CEA level | 1.44 | 0.71–2.93 | 0.318 | |||
Abbreviations: CI=confidence interval; LN=lymph node; LI=lymphatic invasion; VI=vascular invasion; PNI=perineural invasion; CA19-9=carbohydrate antigen 19-9; CEA=carcinoembryonic antigen.